Medical Developments International (MVP) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 FY25 reached $9.1 million, up $1.5 million year-over-year, driven by higher pricing and volume in Pain Management and improved demand in Respiratory segments.

• Penthrox pricing initiatives are expected to deliver $2.5 million in annualized margin improvements in FY25.

• Queensland List of Approved Medicines expanded Penthrox use to all public hospital emergency departments.

• MAGPIE paediatric dossier submitted to European regulators, potentially expanding Penthrox's addressable market.

• New distribution agreement signed for Penthrox in Switzerland with Labatec.

Financial highlights

• Operating cash outflow for Q1 FY25 was $2.7 million, including $2.2 million net investment in working capital and $0.5 million in annual employee incentives.

• Receipts from customers were $9.2 million, $0.9 million higher than Q4 FY24.

• Payments to suppliers and employees totaled $11.8 million, $3.1 million higher than Q4 FY24, reflecting seasonal working capital needs.

• Cash used in investing activities was $0.1 million.

• Cash at 30 September 2024 was $15.8 million.

Outlook and guidance

• Positive momentum in margins and earnings expected to continue in FY25, with underlying EBIT projected to be strongly improved on FY24.

• Positive operating cashflow anticipated by the end of FY25.

• Operational efficiencies and higher average Penthrox prices expected to drive $3-4 million in improvements.